Avidity Biosciences, Inc. - Common Stock (NQ:RNA)

72.31 +0.06 (+0.09%)

Streaming Delayed Price Updated: 9:46 AM EST, Jan 7, 2026 Add to My Watchlist

Price and Volume

Volume	161,209
Open	72.23
Bid (Size)	72.31 (200)
Ask (Size)	72.32 (1,000)
Prev. Close	72.25
Today's Range	72.23 - 72.33
52wk Range	21.51 - 72.61
Shares Outstanding	54,462,518
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Performance

YTD	+0.3%	+0.3%
1 Month	+1.5%	+1.5%
3 Month	+54.0%	+54.0%
6 Month	+147.2%	+147.2%
1 Year	+130.2%	+130.2%

More News

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

Via MarketMinute

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

Via The Motley Fool

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

Via The Motley Fool

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

Via The Motley Fool

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

Via The Motley Fool

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Via The Motley Fool

Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights

November 22, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗

November 20, 2025

Via Benzinga

Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today ↗

November 19, 2025

Via Benzinga

Looking Into Avidity Biosciences Inc's Recent Short Interest ↗

November 19, 2025

Via Benzinga

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

Via MarketMinute

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. (NYSE – WTRG), Cadence Bank (NYSE – CADE), Avidity Biosciences, Inc. (Nasdaq – RNA), Plymouth Industrial REIT, Inc. (NYSE – PLYM)

November 06, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) ↗

October 31, 2025

Via The Motley Fool

Unusual volume stocks in Thursday's session ↗

October 30, 2025

Via Chartmill

$1000 Invested In Avidity Biosciences 5 Years Ago Would Be Worth This Much Today ↗

October 29, 2025

Via Benzinga

RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders

October 28, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 28, 2025

Via Benzinga

This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

October 28, 2025

Via Benzinga

Novartis Maintains Outlook Even As Generics Bite Into Profits ↗

October 28, 2025

Via Benzinga

RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders

October 28, 2025

From Halper Sadeh LLC

Via Business Wire

'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours ↗

October 28, 2025

Via Benzinga

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA

October 27, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Wall Street Soars as Qualcomm Ignites the AI Race ↗

October 27, 2025

Via Chartmill

Frequently Asked Questions

Is Avidity Biosciences, Inc. - Common Stock publicly traded?

Yes, Avidity Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Avidity Biosciences, Inc. - Common Stock trade on?

Avidity Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Avidity Biosciences, Inc. - Common Stock?

The ticker symbol for Avidity Biosciences, Inc. - Common Stock is RNA on the Nasdaq Stock Market

What is the current price of Avidity Biosciences, Inc. - Common Stock?

The current price of Avidity Biosciences, Inc. - Common Stock is 72.31

When was Avidity Biosciences, Inc. - Common Stock last traded?

The last trade of Avidity Biosciences, Inc. - Common Stock was at 01/07/26 09:46 AM ET

What is the market capitalization of Avidity Biosciences, Inc. - Common Stock?

The market capitalization of Avidity Biosciences, Inc. - Common Stock is 3.94B

How many shares of Avidity Biosciences, Inc. - Common Stock are outstanding?

Avidity Biosciences, Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.